GlassScriptPhysician profile
Robin L Sutcliffe
NPI 1730490921
$8,197.47
in general payments reported to CMS, 2019-2025
30 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,289 · 2022: $2,190 · 2023: $2,369 · 2024: $1,156 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,703 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,703.07 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,124.27 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,680.90 | 2021-2024 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $681.19 | 2021-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $630.85 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Novo Nordisk INC | $350.91 | 2021-2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $261.04 | 2023-2024 | Voquezna |
| Genzyme Corporation | $258.65 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $240.88 | 2022-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $214.96 | 2021-2023 | Stelara |
| Gilead Sciences, INC. | $211.95 | 2021-2024 | |
| Qol Medical, LLC | $193.20 | 2021-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $185.51 | 2021-2024 | Ocaliva |
| Celgene Corporation | $184.42 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $157.75 | 2021-2023 | |
| Braintree Laboratories, INC. | $138.68 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $108.84 | 2021-2023 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $89.02 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.32 | 2023-2024 | Cyltezo |
| Evoke Pharma, INC. | $59.48 | 2022-2023 | Gimoti |
| Lilly USA, LLC | $46.98 | 2024 | Omvoh |
| Ardelyx, INC. | $46.55 | 2023-2024 | Ibsrela |
| Amgen INC. | $43.52 | 2022-2023 | Amjevita |
| Redhill Biopharma INC. | $43.27 | 2021 | |
| Ironwood Pharmaceuticals, INC | $39.84 | 2023 | Linzess |
| Pfizer INC. | $32.34 | 2023-2024 | |
| Sandoz INC. | $24.61 | 2024 | Hyrimoz |
| Organon LLC | $22.77 | 2022-2023 | Renflexis |
| Ferring Pharmaceuticals INC. | $22.04 | 2022 | |
| Currax Pharmaceuticals LLC | $16.22 | 2025 | Contrave |
| Vivus LLC | $10.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Sutcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.